Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL.

Authors :: Picardi M
Della Pepa R
Giordano C
Zacheo I
Pugliese N
Mortaruolo C
Trastulli F
Giordano A
Lucignano M
Di Perna M
Raimondo M
Salvatore C
Pane F
Source :: Blood [Blood] 2019 Jan 31; Vol. 133 (5), pp. 498-501. Date of Electronic Publication: 2018 Dec 07.
Publication Year :: 2019

Subjects :: Adult
Aged
Aged, 80 and over
Female
Hepatitis B, Chronic complications
Humans
Lymphoma, Large B-Cell, Diffuse complications
Lymphoma, Large B-Cell, Diffuse drug therapy
Male
Middle Aged
Virus Activation drug effects
Young Adult
Antiviral Agents therapeutic use
Hepatitis B virus drug effects
Hepatitis B, Chronic prevention & control
Lamivudine therapeutic use
Lymphoma, Large B-Cell, Diffuse virology
Tenofovir therapeutic use

Full Text Access

Tools